Metformin Versus Myo-inositol in the Management of Polycystic Ovarian Disease: A Comparative Study

Metformin Versus Myo-inositol in the Management of Polycystic Ovarian Disease: A Comparative Study

In polycystic ovary syndrome (PCOS), changes in physical appearance i.e. weight gain, hirsutism, menstrual disturbances and infertility result in reduced quality-of-life. PCOS is one of the most common endocrine disorders affecting about 4% to 8% of women of reproductive age. Diagnosis is primarily clinical with Rotterdam criteria being the most commonly followed criteria, which require the presence of two out of the three criteria including oligo and/or anovulation, clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries on ultrasound.

The objective of this study is to compare the outcome of Metformin versus Myo-inositol in the management of polycystic ovarian disease.

Inclusion Criteria:

• Married or unmarried
• Diagnosed with PCOS (females presenting with compliant of irregular cycle for >3 months, with hirsutism, acne, presence of polycystic ovaries detected on ultrasound ).

Exclusion Criteria:

• Females already taken or taking PCOS treatment (on medical record)
• Females already enrolled in another trial program
• Females already taking trial drugs
• Females with chronic diabetes (BSR>200 mg/dl), hypertension (BP≥140/90mmHg)
• Females with PCOS along with gestational sac (on ultrasound)
• Females allergic to any content of trial drugs (on history)